Verflixt! Es sieht so aus, als wenn Sie einen veralteten Browser benutzen. Wir empfehlen Ihnen dringend Ihren Browser zu aktualisieren.
Weitere Informationen über Browser und Updates finden Sie hier

Cellectis Bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008, and provides life science researchers with targeted integration products based on Meganuclease-driven Homologous Recombination.

Since its inception in 1999, Cellectis has been a pioneer in the field of genome engineering. Our parent company has extensive experience on meganucleases, meganuclease engineering, TALE Nuclease technology and expertise in biological repair mechanisms such as Homologous Recombination.

Meganucleases are highly specific DNA endonucleases that enable precise modifications of genomic DNA, with applications in the research, bioproduction, agrobiotechnology, and therapeutic sectors.
Since recently Cellectis Bioresearch also offers the new tool called TALEN®'s. A new technology enabling all our customers to do genome customization at any position, at will in any organism or cell line.

Details


Adresse:
Cellectis Bioresearch

rue de la Croix Jarry 8
75013 Paris
Frankreich
Arbeitsgebiet:
Klinische Forschung
Forschung & Entwicklung
Forschung & Lehre
Klinik & Praxis
Sonstige Tätigkeitsfelder
Vertrieb
Expansion:
international
Mitarbeiteranzahl:
51-500
Gründungsjahr:
1999